



## Valbiotis announces its Combined Shareholders General Meeting will be held on May 5, 2022

La Rochelle, April 19, 2022 (5:40 pm CEST) - Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases, announces its Combined Shareholders Meeting will be held on May 5, 2022 and releases the procedures for making available and consulting preparatory documents.

The Shareholders' Meeting will be held at:

Espace ENCAN – Quai Louis Prunier – 17000 La Rochelle  
May 5, 2022, at 5.00 pm

The Shareholders who wish to attend the Shareholders' Meeting must hold an admission card and an identity document.

The means of taking part in the Shareholders' Meeting and the draft proposed resolutions were published in the Bulletin des Annonces Légales Obligatoires (BALO) on March 28, 2022, in Issue No. 37 ([www.journal-officiel.gouv.fr](http://www.journal-officiel.gouv.fr)).

The convening notice, including the agenda and the final resolutions projects, as well as the modalities of participation and vote at the General Meeting, was published on the Company website and in the Bulletin des Annonces Légales Obligatoires (BALO) on April 15, 2022, in Issue No. 45 ([www.journal-officiel.gouv.fr](http://www.journal-officiel.gouv.fr)).

All the documents related to the May 5, 2022 Combined General Meeting, in accordance with Article R.22-10-23 of the French Commercial Code, can be accessed on the Valbiotis website at the following section: <https://www.valbiotis.com/en/general-assemblies/>. They will also be available at the Company headquarters or by mail at: [contact@valbiotis.com](mailto:contact@valbiotis.com).

The documents and information concerning the Shareholders' Meeting will be made available to shareholders as provided by applicable regulations.

In the evolving context of the COVID-19 epidemic and the fight against its spread, the procedures for holding and participating in this Assembly may have to evolve according to health, regulatory and legal imperatives. Shareholders are invited to regularly consult the section dedicated to the 2022 General Meeting on the company's website: <https://www.valbiotis.com/en/general-assemblies/>, which could be updated to specify the definitive modalities of participation in the Meeting, according to the aforementioned imperatives.

## About Valbiotis

Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases in response to unmet medical needs.

Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, relying on a multi-target strategy enabled by the use of plant-based terrestrial and marine resources.

Its products are intended to be licensed to players in the health sector.

Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in Quebec City (Canada).

Valbiotis is a member of the “BPI Excellence” network and has been recognized as an “Innovative Company” by the BPI label. Valbiotis has also been awarded “Young Innovative Company” status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.

For more information about Valbiotis, please visit: [www.valbiotis.com](http://www.valbiotis.com)

## ↳ Contacts

### Corporate communication

#### Valbiotis

Carole ROCHER / Marc DELAUNAY

+33 5 46 28 62 58

[media@valbiotis.com](mailto:media@valbiotis.com)

### Financial communication

#### Actifin

Stéphane RUIZ

+33 1 56 88 11 14

[sruiz@actifin.fr](mailto:sruiz@actifin.fr)



Name: Valbiotis  
ISIN code: FR0013254851  
Mnemonic code: ALVAL  
EnterNext© PEA-PME 150

This press release contains forward-looking statements about Valbiotis' objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as certain risks and uncertainties, including those described in the Valbiotis Universal Registration Document approved by the French Financial Markets Regulator (AMF) on July 27, 2021 (application number R 21-039). This document is available on the Company's website ([www.valbiotis.com](http://www.valbiotis.com)).

This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis' shares or financial securities in any country.